305 studies found for:    Open Studies | bone marrow transplantation
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | bone marrow transplantation
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
2 Recruiting Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
Conditions: Aplastic Anemia;   Non-Cancer Diagnosis
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
3 Recruiting Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Previously Treated Myelodysplastic Syndrome;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia;   Refractory Plasma Cell Myeloma
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
4 Not yet recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
5 Not yet recruiting Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Procedure: Autologous bone marrow transplantation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Alemtuzumab
6 Recruiting Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
Condition: Adult Acute Myeloid Leukemia in Remission
Interventions: Procedure: Bone Marrow Transplantation;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sorafenib Tosylate
7 Recruiting Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
8 Recruiting Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Autologous bone marrow transplantation;   Procedure: Allogeneic bone marrow transplantation
9 Recruiting Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Other: Biological: Bone Marrow Transplant
10 Recruiting Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation;   Drug: Treosulfan
11 Recruiting Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Non-Malignant
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
12 Not yet recruiting Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
Conditions: Acute Myeloid Leukemia in Remission;   Primary Myelofibrosis;   Primary Myelofibrosis, Prefibrotic Stage;   Secondary Acute Myeloid Leukemia;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
13 Recruiting Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Condition: Autoimmune Disorder
Interventions: Biological: anti-thymocyte globulin;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: prednisone;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
14 Recruiting Non-Myeloablative Conditioning and Bone Marrow Transplantation
Conditions: Sickle Cell Disease;   Hemoglobinopathies
Interventions: Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
15 Recruiting Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
16 Recruiting Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carfilzomib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan
17 Recruiting Bone Marrow Transplantation to Promote Follicle Recruitment in Poor Ovarian Reserve
Condition: Ovarian Reserve
Intervention: Drug: Bone marrow transplant into ovarian artery
18 Recruiting Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
19 Recruiting Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Secondary Acute Myeloid Leukemia
Interventions: Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8;   Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8;   Drug: Fludarabine Phosphate;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
20 Recruiting Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders
Condition: Sickle Cell Disease
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years